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A B S T R A C T
Gypenosides (GP) are a type of traditional Chinese medicine (TCM) extracted from plants and commonly applied
for treatment of metabolic diseases. This study aims to explore the effects of GP extracts on alleviating non-
alcoholic fatty liver disease (NAFLD). In this experiment, C57BL/6 J mice were randomly assigned into normal
diet control (ND), HFHC (high-fat and high-cholesterol) and HFHC+GP (GP) groups. Mice in HFHC group were
fed HFHC diet combined with fructose drinking water for 12 weeks to induce the animal model of NAFLD,
followed by ordinary drinking water until the end of the experiment. In the HFHC+GP group, mice were fed
HFHC diet combined with fructose drinking water for 12 weeks, followed by GP-containing drinking water till
the end. Mouse body weight was measured weekly. After animal procedures, mouse liver and serum samples
were collected. It is shown that GP administration reduced body weight, enhanced the sensitivity to insulin
resistance (IR) and decreased serum levels of ALT, AST and TG in NAFLD mice. In addition, GP treatment
alleviated steatohepatitis, and downregulated ACC1, PPARγ, CD36, APOC3 and MTTP levels in mice fed with
HFHC diet. Furthermore, GP treatment markedly improved intestinal microbiota, and reduced relative abun-
dance ratio of Firmicutes / Bacteroidetes in the feces of NAFLD mice. Our results suggested that GP alleviated
NAFLD in mice through improving intestinal microbiota.
1. Introduction
NAFLD is a type of chronic liver disease caused by non-alcoholic
factors. The incidence of NAFLD in Western countries is about
30%–40%, which is 15%–20% in females [1]. The prevalence of NAFLD
in Chinese urban population is about 15% [2]. NAFLD is the risk factor
to increase susceptibilities to type 2 diabetes mellitus (T2DM), cardio-
vascular disease (CVD), and chronic kidney disease [3]. In addition,
approximately 20% NAFLD patients would progress to non-alcoholic
steatohepatitis and even hepatic carcinoma [4]. The pathogenesis of
NAFLD is mainly attributed to IR. Once IR occurs, insulin inhibits li-
polysis of adipose tissues and hepatic gluconeogenesis. Moreover, in-
sulin promotes steatohepatitis by stimulating de novo synthesis of liver
lipids, eventually progressing to NAFLD [5]. In recent years, the in-
cidence of NAFLD is on the rise, and seriously endangers human health
[6]. Effective drugs targeting NAFLD are lacked and it is urgent to
clarify the pathogenesis of NAFLD [7].
GP are perennial vines widely grown in Asian, and their leaves have
been processed in food and tea [8]. Previous studies have demonstrated
that GP are beneficial to treatment of obesity [9], CVD [10], T2DM [11]
and cancers [12,13]. It is reported that GP administration reduces body
weight, liver weight and blood cholesterol levels in ob/ob mice by
activating AMPK [14]. Liu et al. showed that GP can stimulate activities
of brown fat cells and promote the conversion of white fat to brown fat
[15]. Therefore, GP may be promising drugs utilized for NALFD treat-
ment.
Intestinal microbiota is of significance in the progression of NAFLD
[16]. By analyzing the composition of fecal flora in genetically obese
mice, elevated ratio of Firmicutes / Bacteroidetes is identified to be
related to obesity [17]. Another study reported that transplanting cold
microbiota into sterile mice can enhance the insulin sensitivity of the
host and cold tolerance through inducing the conversion of white fat to
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brown fat. Cold microbiota transplantation also reduces fat accumula-
tion and increases energy consumption [18].
Through literature review, GP are believed to promote fat metabo-
lism, which is closely linked to intestinal microbiota. Based on these
findings, we proposed that GP may be beneficial to NALFD treatment
through improving intestinal microbiota, which was specifically ex-
plored in this paper.
2. Materials and methods
2.1. Materials and diet
GP (purity> 80%, determined by HPLC) were offered by Shanxi
Baicaocui Biological Technology, 190306 (Supplement Fig. 1). HFHC
diet was provided by Research Diets Inc, D12079B and fructose was
from Merck Life Science (Shanghai) Co. Ltd, F0127.
2.2. Animals and groups
Twenty-five six-week-old C57BL/6 J mice were provided by Xiamen
University Experimental Animal Center (18070480730001). Animal
procedures were examined by Medical Ethics Committee of Xiamen
University. Every 5 mice were housed in one polycarbonate cage in an
environment of 25 ± 1 °C, 40–60% humidity and 12 h/12 h dark/light
cycle. After one-week habituation, 5 mice were fed normal diet and
water, and the remaining were fed HFHC diet and fructose water
(0.02 g/ml) for 12 weeks to induce the in vivo NAFLD model [19].
Afterwards, these 20 mice were assigned into two groups with HFHC
diet and GP-containing water (300mg/kg) or normal drinking water for
6 weeks. All diets were preserved at 4℃ and replaced every three days.
Body weight of each mouse was weekly recorded. At last, mice were
fasting for 12 h and anesthetized by 7% chloral hydrate (0.05 mL/10 g).
Blood, abdominal fat, liver and intestinal contents of mice were col-
lected.
2.3. Insulin tolerance test (ITT) and intra-peritoneal glucose tolerance test
(IPGTT)
At the 18th week of animal procedures, mice were fasting for 6 h
and intraperitoneally injected with 0.75 unit/kg insulin (Eli Lilly) for
performing ITT. On the next day, mice were fasting for 18 h and in-
traperitoneally injected with 2.0 g/kg glucose (Sigma-Aldrich) for per-
forming IPGTT. Glucose levels were determined at 0, 15, 30, 60 and
120 h after injection, respectively, using a portable blood glucose meter
(ACCU-CHEK Performa, Roche Diabetes Care, Germany,
79527612734). Glucose concentration - time point plots were depicted
to calculate AUC (area under curves) of ITT and IPGTT [20].
2.4. Determination of AST, ALT, TG and HOMA-IR in serum
Blood samples were collected from mouse eyeballs and placed at
room temperature (RT) for 1 h. After centrifugation at 3500 rpm for
10min, serum samples were collected for determination of TG, ALT and
AST levels using commercial kits (Nanjing Jiancheng Bioengineering
Institute, A110-1, Solarbio Science & Technology Co., Ltd, Beijing,
BC1555 and BC1565). Plasma insulin level was determined by ELISA
(ALPCO, 80-INSMSU-E01). HOMA-IR was finally calculated based on
the following formula: HOMA-IR=Fasting insulin concentration (mU/
L) × fasting blood sugar (FBS, mmol/L) / 22.5 [21].
2.5. Histopathological and Oil-Red-O examination of liver tissues
Mouse hepatic lobules were immersed in 4% paraformaldehyde,
paraffin embedded, sliced and dehydrated. Sections were subjected to H
&E staining and observed for steatosis under a microscope (magnifi-
cation 200×). Steatotic liver tissues were pathologically examined for
evaluating their histopathological grade.
For Oil-Red-O examination, liver tissues were immersed in 4%
paraformaldehyde for 10min, washed with PBS for three times and
immersed in 60% isopropanol for 10 s. Subsequently, tissues were dyed
with 0.3% oil-red solution for 1min, washed in 60% isopropanol and
PBS, and finally observed under a microscope (magnification 200×).
2.6. RNA isolation and quantitative real-time PCR (qRT-PCR)
Total RNA in mouse liver tissues was extracted using TRIzol reagent
(Life Technologies, CA, USA) and the concentration and qualification
were measured on NanoDrop 2000 Spectrophotometer. Qualified RNA
was reversely transcribed into cDNA using the PrimeScript™RT reagent
Kit with gDNA Eraser (Takara, Tokyo, Japan) and amplified using TB
Green™ Premix Ex Taq™ (Takara, Tokyo, Japan). Relative levels were
calculated using 2−ΔΔCT method. Prime sequences were listed in
Supplement Table 1.
2.7. Immunohistochemistry (IHC)
IHC examinations were carried out on 3mm thick sections. Primary
antibodies for IHC were unmasked in 10mM sodium citrate buffer (pH
6.0) at 90 °C for 30min. Sections were immersed in 0.03% hydrogen
peroxide for 10min at RT to inactivate endogenous peroxidase. They
were immersed in blocking serum [PBS containing 0.04% bovine serum
albumin (A2153, Sigma-Aldrich, Shanghai, China) and 0.5% normal
goat serum (X0907, Dako Corporation, Carpinteria, CA, USA)] for
30min at RT. Subsequently, sections were reacted with primary anti-
bodies [anti-CD36, anti-PPARγ, anti-SOD and anti-ACC1 (18836-1-AP,
Proteintech, USA)] overnight at 4 °C. Sections were then washed three
times for 5min in PBS. Non-specific was antibodies were blocked with
0.5% casein and 5% normal serum for 30min at RT. Finally, IHC
staining was developed using diaminobenzidine substrate, and sections
were counterstained with hematoxylin.
2.8. 16S rDNA bioinformatics analysis and statistics
The genomic DNA of mouse fecal sample was extracted using a DNA
extraction kit (Qiagen, Germantown, MD USA). The extracted DNA was
subjected to PCR amplification for V3-V4 variable region of 16S ribo-
somal RNA gene in bacteria. Primers used for 16S rDNA bioinformatics
were as follows: 338F: 5′-ACTCCTACGGGAGGCAGCAG-3′ and 806R:
5′-GGACTACHVGGGTWTCTAAT-3′. Biterminal sequencing was con-
ducted based on the standard protocols on the Illumina MiSeq platform
in triplicate. Raw data were submitted to the SILVA (SSU and LSU
databases 128) database. OTU (Operational Taxonomic Units) analysis
under 97% similar level, multivariate analysis and significant test were
performed [22].
2.9. Statistical processing
SPSS 18.0 was used for data analyses and GraphPad Prism 8.0 was
used for figure editing. Data were expressed as mean ± standard de-
viation. Differences between two groups were analyzed by variance
analysis. P < 0.05 was considered as statistically significant.
3. Results
3.1. GP alleviate body weight, liver weight and improve IR in NAFLD mice
Mouse body weight was weekly recorded and liver tissues were
harvested and weighed after sacrifice. After the 18-week experimental
period, changes in body weight of each group were depicted (Fig. 1A).
Mice in HFHC group started to gain body weight at the 4th week, which
was markedly heavier at the 18th week relative to that in ND group
(Fig. 1B). Body weight in GP group was reduced relative to HFHC group
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(Fig. 1B). Mouse liver weight was larger in HFHC group than ND group
and GP group (Fig. 1C). To assess the influence of GP on NAFLD-in-
duced changes in glucose levels, FBS was determined at five time
points. FBS in GP group was similar to that in ND group, and markedly
lower than that in HFHC group (Fig. 1F). However, ITT was similar
among each group (Fig. 1G). HFHC diet enhanced HOMA-IR in mice,
which was reduced by GP treatment (Fig. 1H). The above data de-
monstrated the ability of GP to reduce NAFLD-induced body weight and
liver weight gain, as well as to enhance insulin sensitivity.
3.2. GP alleviate hyperlipidemia in NALFD mice
HFHC feeding markedly enhanced serum levels of ALT, AST and TG
in mice, and were further reversed to the normal levels by GP treatment
(Fig. 2A–C). Hence, GP were capable of alleviating NALFD-induced
hyperlipidemia.
3.3. GP alleviate HFHC feeding-induced pathological lesions in mouse liver
and intestines
H&E and Oil-Red-O staining revealed severe steatohepatitis and
neutrophil inflammatory aggregation in mouse liver tissues of HFHC
Fig. 1. The effect of GP on body weight, glucose tolerance and insulin sensitivity. A. Body weight change of mice. B. Quantification of the area under the curve (AUC)
from the body weight. C. Liver weight of mice. D. Effect of GP on the glucose tolerance was determined by intraperitoneal glucose tolerance test (IPGTT). E. Effect of
GP on the glucose tolerance was determined by insulin tolerance test (ITT). F. Quantification of the area under the curve (AUC) from the IPGTT. G. Quantification of
the area under the curve (AUC) from the ITT. H. Homeostasis model assessment-insulin resistance (HOMA-IR). Statistical analyses were conducted with one-way
ANOVA. *P < 0.05, ***P < 0.001 versus ND; ##P < 0.01, ###P < 0.001 versus HFHC.
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group (Fig. 2D). GP treatment markedly alleviated these pathological
lesions (Fig. 2E, F). In addition, GP improved colonic lymphitis caused
by HFHC diet (Supplement Fig. 2).
3.4. GP downregulate key genes related to lipid metabolism
QRT-PCR and IHC were conducted to determine the influence of GP
on expressions of key genes associated with lipid metabolism. The
mRNA levels of ACC1, PPARγ, CD36, APOC3 and MTTP were markedly
upregulated after HFHC feeding, while ACC2 level remained un-
changeable. GP treatment reversed the upregulated lipid metabolism-
associated genes (Fig. 3A). IHC also revealed the same trends that GP
treatment reduced positive expressions of CD36, ACC1, PPARγ and
SOD1 in mice of HFHC group (Fig. 3B).
3.5. GP enhance intestinal microbiota diversity in NAFLD mice
The α diversity is reflected by the Shannon index [23]. In the
Shannon dilution curve, the curve of each sample tended to be smooth,
indicating that the sequencing depth was sufficient to reveal the bio-
diversity in the sample (Fig. 4A). Venn diagrams depicted much more
diversities in ND group than those in HFHC and GP group, which was
Fig. 2. The effect of GP on serum levels of ALT, AST, TG and liver pathological lesions. The effect of GP on serum ALT (A), AST (B) and TG (C). Representative images
of liver section stained with H&E (magnification: 200×) and Oil-red-O (magnification: 200×) (D). Liver steatosis grade examined in H&E (E), and liver lobular
inflammation examined in Oil-red-O. **P < 0.01, ***P < 0.001 versus ND; ##P < 0.01, ###P < 0.001 versus HFHC.
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the lowest in HFHC group (Fig. 4B). Unweighted UniFrac principal
coordinates analysis (PCoA) illustrated a significant difference in the
distribution of intestinal microbiota among the three groups. Particu-
larly, intestinal microbiota was much more abundant in GP group than
that in HFHC group, and was similar to that in ND group (Fig. 4C).
3.6. GP alleviate HFHC-induced intestinal microbiota disorder
Firmicutes and Bacteroidetes have relative abundances of
approximately 90%, presenting absolute advantage in all intestinal
microbiota (Fig. 4D). The ratio of Firmicutes / Bacteroidetes has been
considered to be a key indicator reflecting microbiota changes. It is
positively correlated with obesity and other metabolic diseases
[24,25].In our experiment, the abundance of Firmicutes was similar
among the three group. However, the abundance of Bacteroidetes was
much lower in HFHC group relative to ND (Fig. 4E) and GP group
(Fig. 4F). The ratio of Firmicutes / Bacteroidetes markedly increased in
HFHC group, whereas it decreased in GP group (Fig. 4G). Long-term
Fig. 3. Expressions of lipid metabolites in liver tissues. The mRNA expressions of lipogenesis-related genes including ACC1, ACC2, PPARγ, CD36, APOC3 and MTTP
normalized to β-actin (A). Protein levels of CD36, ACC1, PPARγ and SOD1 were verified by IHC in liver tissues (B). **P < 0.01, ***P < 0.001 versus ND;
###P < 0.001 versus HFHC.
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HFHC diet resulted in the dysregulated Firmicutes / Bacteroidetes,
which was improved by GP treatment.
Subsequently, the heatmap uncovered abundances of 52 key flora at
genus level (Fig. 5A). Totally, three kinds of flora exhibited pronounced
differences, namely Rikenellaceae_RC9_gut_group, Fissicatena and Ak-
kermansia. In particular, the latter two showed higher abundances in
HFHC group, which were reversed in GP group (Fig. 5B, C). Moreover,
HFHC feeding enhanced the abundance of Rikenellaceae in mouse in-
testine, while no significant difference was discovered (Supplement
Fig. 3). The above results indicated that GP can restore HFHC-induced
dysbiosis of the intestinal microbiota and maintain the intestinal health.
To compare the differences in metabolic pathways between the HFHC
and GP groups, KEGG analysis was performed. Significant differences in
metabolic pathways such as energy metabolism, glycan biosynthesis
and metabolism were seen between GP and HFHC group (Fig. 5D).
4. Discussion
Hepatic steatosis is not only a prerequisite for the development of
NAFLD, but also a key event involving in metabolic dysfunction.
Therefore, improvement of steatosis and lipid metabolism disorder are
priorities in the treatment course. Effective drugs targeting steatosis are
lacked currently [26,27]. GP, as TCM, contain a variety of biologically
active ingredients. Among them, saponins can reduce steatohepatitis by
autophagy regulation [28] and carbon tetrachloride (ccl4)-induced
liver fibrosis in rats [29]. Flavone can induce hepatocyte death [30].
Polysaccharide is one of the main components of GP with anti-oxidation
capacity, which is able to regulate immune activity and alleviate liver
damage [31]. Hence, GP are believed to alleviate NAFLD. In this paper,
GP effectively reduced body weight and improved steatohepatitis in
NAFLD mice. In addition, IR and decreased serum levels of AST, ALT
and TG in NAFLD mice were alleviated by GP treatment. Moreover, GP
could remarkably improve pathological lesions in liver tissues owing to
HFHC diet (Fig. 6).
Fig. 4. The effect of GP on diversity and abundance of gut microbiota. Shannon index value indicated the diversity of the samples (A); OTU Venn analysis of samples
of different groups (B); PCoA of the between samples distances (beta diversity) computed using unweighted unifrac distance (C). Relative abundance analysis in
phylum level (D). Relative abundance of Bacteroidetes and Firmicutes at the phylum level (E). ***P < 0.001 versus ND; ##P < 0.01 versus HFHC.
X. Huang, et al. Biomedicine & Pharmacotherapy 118 (2019) 109258
6
For de novo lipogenesis (DNL), ACC1 and ACC2 are two crucial
enzymes participating in this process. ACC1, a cytosolic enzyme, par-
ticipates in the rate-limiting step in DNL. ACC2, a mitochondrial
membrane associated enzyme, could generate malonyl-CoA primarily,
and inhibit CPT-1 and transports long chain fatty acid transport into
mitochondria [32,33]. Therefore, ACC can increase liver fat deposition
and lead to steatohepatitis. Fatty acids can be oxidized in mitochondria
and peroxisomes. SOD activates the antioxidant pathway to cause ex-
cess ROS, leading to increase in mitochondria and peroxidase β-oxi-
dation [34]. High levels of free fatty acid (FFA) activate PPARγ via the
liver X receptor and pregnane X receptor, which in turn upregulate
CD36 level in hepatocytes [35]. Meanwhile, the liver esterifies the in-
gested FFA into triacylglycerol, and the latter forms VLDL and releases
it into blood. VLDL transports the lipid from liver to peripheral tissues,
where MTTP contributes triglycerides to synthesize chylomicrons.
APOC3 is an important component of VLDL, and both MTTP and
APOC3 activation lead to lipid deposition [36–38]. Our findings
showed upregulation of ACC1, PPARγ, CD36, MTTP and APOC3 in mice
of HFHC group, which were reversed by GP treatment. IHC analysis
further confirmed their positive expressions in mouse liver tissues.
Therefore, GP could alleviate NALFD-induced pathological state of
NAFLD through regulating key genes associated with liver lipid
Fig. 5. Intestinal microbiota analysis at the genus level. Heatmap of the abundance of 52 key species in response to GP treatment (A). Relative abundance of
Fissicatena (B) and Akkermansia (C) in the ND, HFHC and HFHC-GP groups. Pathway enrichment analysis of the HFHC and HFHC-GP groups (D). The y-axis
indicated differential pathways, and x-axis indicated the abundance of differential pathway. In the right part, the y-axis was P value and x-axis was CI of pathway
abundance. *P < 0.05, **P < 0.01 versus ND; #P < 0.05, ##P < 0.01 versus HFHC.
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metabolism.
Abundant microorganisms are present in intestines, exhibiting
fundamental roles in the body [39]. It is reported that intestinal mi-
crobial disorders are one of the important factors leading to obesity
[40]. In this paper, 16 s rDNA analysis revealed that the bacterial bio-
diversity of mice in HFHC group was markedly lower than that of the
ND group, and it was higher in GP group than that of HFHC group. No
significant changes in the composition of intestinal microbiota were
identified among the three groups. Bacteroides and Firmicutes are the
most abundant microbial species in the host microbiota. Bacteroides is
involved in the absorption and degradation of host polysaccharides,
exerting a dominant role in the intestinal ecosystem [41]. A recent
study showed that the ratio of Firmicutes / Bacteroidetes is elevated in
intestines of obese adults and children [42]. Our findings uncovered
that GP treatment reduced relative abundance ratio of Firmicutes /
Bacteroidetes in the feces of NAFLD mice.
Akkermansia is ascertained as a human intestinal mucin-degrading
bacterium, accounting for 3–5% of the microbial population in healthy
humans [43]. A relevant study found that the abundance of Akker-
mansia is negatively correlated with body weight and obesity in mice
and humans [44]. A clinical study has shown that Fissicatena is highly
abundant in the intestinal tract of cirrhosis patients and positively
correlated with the production of SCFAs [45]. Our results illustrated the
promotive effects of GP on abundances of Akkermansia and Fissicatena
in intestines of NAFLD mice. In addition, KEGG enrichment analysis
showed that intestinal microbiota in GP-fed mice were mainly enriched
in metabolic pathways, including energy metabolism, glycan bio-
synthesis and metabolism. The above studies showed that GP can sig-
nificantly improve intestinal microbiota, thereby alleviating the pro-
gression of NAFLD.
5. Conclusions
GP alleviate NAFLD-induced body weight gain, IR and upregulated
key genes associated with lipid metabolism. Besides, GP improve
NAFLD through enhancing the abundance of intestinal microbiota.
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